Vortrag
SUSTAINED CLINICAL BENEFIT IN PATIENTS WITH LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD) RECEIVING LONG-TERM TRIHEPTANOIN (UX007) AND IN PATIENTS TRIHEPTANOIN TREATMENT-NAÏVE: RESULTS FROM AN OPEN-LABEL, LONG-TERM, SAFETY AND EFFICACY EXTENSION STU
Speaker